A new era in the treatment of systemic juvenile idiopathic arthritis

New England Journal of Medicine

Volumn 367, Issue 25, 2012, Pages 2439-2440

  Sandborg, Christy ^a   Mellins, Elizabeth D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; PLACEBO; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LIVER DYSFUNCTION; MACROPHAGE ACTIVATION SYNDROME; MEDICAL SOCIETY; NEUTROPENIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; UNITED STATES;

EID: 84871316266     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1212640     Document Type: Editorial

References (9)

1. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
2. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
3. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86. (Pubitemid 40664091)
4. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5. (Pubitemid 39336738)
5. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25. (Pubitemid 40365104)
6. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7:416-26.
7. Kimura YW, Haroldsom JE, Lee KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012 November 8 (epub ahead of print).
8. Schmitz ML, Weber A, Roxlau T, Gaestel M, Kracht M. Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines. Biochim Biophys Acta 2011;1813:2165-75.
9. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as firstline disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multi-center series. Arthritis Rheum 2011;63:545-55.